Basic mechanisms responsible for osteolytic and osteoblastic bone metastases

Clinical Cancer Research

Volumn 12, Issue 20 PART 2, 2006, Pages

  Guise, Theresa A ^a,e   Mohammad, Khalid S ^a   Clines, Gregory ^a   Stebbins, Elizabeth G ^b   Wong, Darren H ^b   Higgins, Linda S ^b   Vessella, Robert ^c   Corey, Eva ^b   Padalecki, Susan ^a   Suva, Larry ^d   Chirgwin, John M ^a   Pearse, ^f   Roodman, ^f   Lipton, ^f   Clohisy, ^f   Weilbaecher, ^f   Smith, ^f  

^a UNIVERSITY OF VIRGINIA   (United States)

^b SCIOS INC   (United States)

^c UNIVERSITY OF WASHINGTON   (United States)

^d UNIVERSITY OF ARKANSAS FOR MEDICAL SCIENCES   (United States)

^e UNIVERSITY OF VIRGINIA   (United States)

^f NONE

Author keywords

[No Author keywords available]

Indexed keywords

ENDOTHELIN 1; PARATHYROID HORMONE;

BONE METASTASIS; BONE TURNOVER; BREAST CANCER; DISEASE ASSOCIATION; HUMAN; OSSIFICATION; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TUMOR GROWTH;

BONE NEOPLASMS; BREAST NEOPLASMS; FEMALE; HUMANS; MALE; NEOPLASM METASTASIS; OSTEOBLASTS; OSTEOCLASTS; OSTEOLYSIS; PROSTATIC NEOPLASMS;

EID: 33750738067     PISSN: 10780432     EISSN: None     Source Type: Journal    
DOI: 10.1158/1078-0432.CCR-06-1007     Document Type: Review

References (26)

1. Roodman GD. Mechanisms of bone metastasis. N Engl J Med 2004;350:1655-64.
2. Mundy GR. Metastasis to bone: causes, consequences, and therapeutic opportunities. Nat Rev Cancer 2002;2:584-93.
3. Roudier MP, Vesselle H, True LD, et al. Bone histology at autopsy and matched bone scintigraphy findings in patients with hormone refractory prostate cancer: the effect of bisphosphonate therapy on bone scintigraphy results. Clin Exp Metastasis 2003;20:171-80.
4. Bendre MS, Margulies AG, Walser B, et al. Tumor-derived interleukin-8 stimulates osteolysis independent of the receptor activator of nuclear factor-κB ligand pathway. Cancer Res 2005;65:11001-9.
5. Kakonen SM, Selander KS, Chirgwin JM, et al. Transforming growth factor-κ stimulates parathyroid hormone-related protein and osteolytic metastases via Smad and mitogen-activated protein kinase signaling pathways. J Biol Chem 2002;277:24571-8.
6. Yin JJ, Selander K, Chirgwin JM, et al. TGF-β signaling blockade inhibits PTHrP secretion by breast cancer cells and bone metastases development. J Clin Invest 1999;103:197-206.
7. Guise TA, Yin JJ, Taylor SD, et al. Evidence for a causal role of parathyroid hormone-related protein in the pathogenesis of human breast cancer-mediated osteolysis. J Clin Invest 1996;98:1544-9.
8. Kang Y, Siegel PM, Shu W, et al. A multigenic program mediating breast cancer metastasis to bone. Cancer Cell 2003;3:537-49.
9. Kang Y, He W, Tulley S, et al. Breast cancer bone metastasis mediated by the Smad tumor suppressor pathway. Proc Natl Acad Sci U S A 2005;102:13909-14.
10. Dallas SL, Rosser JL, Mundy GR, Bonewald LF. Proteolysis of latent transforming growth factor-β (TGF-β)-binding protein-1 by osteoclasts: a cellular mechanism for release of TGF-β from bone matrix. J Biol Chem 2002;277:21352-60.
11. Brown JE, Cook RJ, Major P, et al. Bone turnover markers as predictors of skeletal complications in prostate cancer, lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97:59-69.
12. Coleman RE, Major P, Lipton A, et al. Predictive value of bone resorption and formation markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin Oncol 2005;23:4925-35.
13. Oefelein MG, Ricchiuti V, Conrad W, et al. Skeletal fractures negatively correlate with overall survival in men with prostate cancer. J Urol 2002;168:1005-7.
14. Zudaire E, Martinez A, Cuttitta F. Adrenomedullin and cancer. Regul Pept 2003;112:175-83.
15. Nelson J, Bagnato A, Battistini B, Nisen P. The endothelin axis: emerging role in cancer. Nat Rev Cancer 2003;3:110-6.
16. Yin JJ, Mohammad KS, Kakonen SM, et al. A causal role for endothelin-1 in the pathogenesis of osteoblastic bone metastases. Proc Natl Acad Sci U S A 2003;100:10954-9
17. Nelson JB, Hedican SP, George DJ, et al. Identification of endothelin-1 in the pathophysiology of metastatic adenocarcinoma of the prostate. Nat Med 1995;1:944-9.
18. Carducci MA, Padley RJ, Breul J, et al. Effect of endothelin-A receptor blockade with atrasentan on tumor progression in men with hormone-refractory prostate cancer: a randomized, phase II, placebo-controlled trial. J Clin Oncol 2003;21:679-89.
19. Mohammad KS, Wang Z, Martinez A, et al. Adrenomedullin is made by prostate cancers and increases both osteolytic and osteoblastic bone metastases. J Bone Miner Res 2004;19:S25.
20. Yi B, Williams PJ, Niewolna M, Wang Y, Yoneda T. Tumor-derived platelet-derived growth factor-BB plays a critical role in osteosclerotic bone metastasis in an animal model of human breast cancer. Cancer Res 2002;62:917-23.
21. Tian E, Zhan F, Walker R, et al. The role of the Wnt-signaling antagonist DKK1 in the development of osteolytic lesions in multiple myeloma. N Engl J Med 2003;349:2483-94.
22. Clines GA, Mohaddad KS, Wessner LL, Chirgwin JM, Guise TA. Endothelin-1 stimulates bone formation by regulating osteoblast secretion of the paracrine regulators IL-6, Cyr61, CTGF, and Dkk1. J Bone Miner Res 2005;20:S249.
23. Schluter KD, Katzer C, Piper HM. A N-terminal PTHrP peptide fragment void of a PTH/PTHrP-receptor binding domain activates cardiac ET(A) receptors. Br J Pharmacol 2001;132:427-32.
24. Saad F, Gleason DM, Murray R, et al; Zoledronic Acid Prostate Cancer Study Group. Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer. J Natl Cancer Inst 2004;96:879-82.
25. Smith MR, Lee WC, Brandman J, Wang Q, Botteman M, Pashos CL. Gonadotropin-releasing hormone agonists and fracture risk: a claims-based cohort study of men with nonmetastatic prostate cancer. J Clin Oncol 2006;23:7897-903.
26. Smith MR, McGovern FJ, Zietman AL, et al. Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer. N Engl J Med 2001;345:948-55.